New IQVIA Study Demonstrates Cost and Time Savings of Decentralized Trials


IQVIA announced new evidence that decentralized clinical trials (DCTs) deliver measurable benefits for patients, sites, and sponsors.

In this analysis decentralized trials were assessed against 14 metrics across three categories—productivity, quality, and trial delivery, to determine how a DCT approach compared to traditional study models. The analysis found that sponsors can achieve faster, less expensive, and more engaging trials using DCT driven protocols.

Read more about the study here.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.